Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors

Podobne knjige/članki

• Identification of Human S100A9 as a Novel Target for Treatment of Autoimmune Disease via Binding to Quinoline-3-Carboxamides
  od: Björk, Per, et al.
  Izdano: (2009)
• Quinoline-3-carboxamides such as tasquinimod are not specific inhibitors of S100A9
  od: Pelletier, Martin, et al.
  Izdano: (2018)
• The anti-tumor effect of the quinoline-3-carboxamide tasquinimod: blockade of recruitment of CD11b(+) Ly6C(hi) cells to tumor tissue reduces tumor growth
  od: Deronic, Adnan, et al.
  Izdano: (2016)
• The long and winding road for the development of tasquinimod as an oral second-generation quinoline-3-carboxamide antiangiogenic drug for the treatment of prostate cancer
  od: Isaacs, John T
  Izdano: (2010)
• Erratum to: The anti-tumor effect of the quinoline-3-carboxamide tasquinimod: blockade of recruitment of CD11b(+) Ly6C(hi) cells to tumor tissue reduces tumor growth
  od: Deronic, Adnan, et al.
  Izdano: (2016)